Bernd Hoppe

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

The Oxalosis & Hyperoxaluria Foundation is dedicated to eradicating all forms of hyperoxaluria disease forever. The non-profit company is based in New York, NY. The company's vision is a world without hyperoxaluria, and they are committed to improving the daily lives of people with this condition.